Servier Pharmaceuticals shared a post on LinkedIn:
“We were proud to join fellow industry leaders at the 2025 Citeline Scrip Awards!
It was an honor to have our therapy for Grade 2 IDH-mutant glioma recognized as a finalist for Best New Drug. We are more motivated than ever to continue driving progress forward for patients with glioma.”
More posts about Glioma.
